In contrast, the anti-CCRL2 ADC exhibited consistent efficacy across the different cell line subtypes, demonstrating higher activity against cell lines derived from patients with TP53 mutated MDS/AML or AML with erythroid features compared to gemtuzumab and PBD-conjugated ADCs targeting CD33 and CD123. The gene discussed is TP53; the disease is acute myeloid leukemia.